Aireen diagnostic scope

On the market

Diabetic retinopathy is a severe, sight-damaging complication of diabetes. Early diagnosis minimises the risk of fatal complications and sight loss. For this reason, everyone with diabetes should undergo an eye examination every year. More than 40% of patients do not undergo regular examination, however. Aireen® allows for fast, precise, pain-free and accessible eye screening for patients with diabetes.

In just 60 seconds, Aireen® assesses a retina image with high precision.

  • Secure - High sensitivity and very low on false positives
  • Comfortable - Result in less than 60 seconds
  • Prooven - through clinical trials

Since May 2023 Aireen® diabetic retinopathy screening has been certified as class IIb EU-MDR medical device.

In development

Age-related macular degeneration (AMD) is a disease of the retina and is the most common cause of sight loss amongst older people, occurring in over 8% of the population over 50.

Planned Aireen AMD screening assesses an image of the retina in 30 seconds, and confirms or rejects the presence of disease symptoms.

In development

Glaucoma is a disease which results in progressive damage to the optic nerve. Left untreated, glaucoma can result in blindness.

Across the world, around 1.5 to 2% of the population over 40 suffer from glaucoma-related optic nerve damage.

Planned Aireen glaucoma screening assesses an image of the retina in 30 seconds, and with high precision detects changes in the image which indicate the suspected presence of the disease.

Our awards